LG unveils improved pathology AI model, EXAONE Path 2.0
The logo of LG Group is seen outside its headquarters building Yeouido, Seoul, in this undated file photo. Korea Times file
LG AI Research, the artificial intelligence (AI) lab under South Korea's LG Group, said Wednesday it has unveiled its upgraded pathology AI model, EXAONE Path 2.0.
Compared with the previous 1.0 version, EXAONE Path 2.0 delivers enhanced accuracy in analyzing and predicting genetic mutations, gene expression patterns and subtle structural changes in human cells and tissues, using pathological tissue images, according to LG AI Research.
It noted that the model has been trained on over 10,000 datasets where whole slide images are paired with multiomics information, enabling it to predict gene activity solely through image analysis without the need for expensive genomic testing.
"With EXAONE Path 2.0, genetic testing can be completed in under one minute, compared with the more than two weeks it used to take," Park Yong-min, a lead researcher at LG AI Research, said. "This will help secure the golden time for cancer patient treatment."
He added that doctors and pharmaceutical companies can use EXAONE Path 2.0 to rapidly analyze cancer patients' pathological images, identify gene mutations and select appropriate targeted therapies.
Meanwhile, LG AI Research said it has partnered with professor Hwang Tae-hyun from Vanderbilt University Medical Center to jointly develop a multimodal medical AI platform.
Hwang, the founding director of the Center for Molecular AI at Vanderbilt, leads research on integrating AI with molecular biology to advance cancer research, transplant science and precision medicine.